Agent Is A Biotechnology Company Focused On Developing A Blood-based Diagnostic Test For The Early Detection Of Alzheimer's Disease. Their Innovative Approach Aims To Identify The Disease Up To 20 Years Before Irreversible Symptoms Appear. By Utilizing Machine Learning, Multiomics Biomarkers, And Artificial Intelligence, Agent Analyzes Proteins And Metabolites In Blood Plasma To Decode The Body's Response To Alzheimer's During Its Silent Phase. The Company's Core Product Is A Multiomics Platform That Integrates Computational Biology And AI To Detect Alzheimer's At Various Stages, Including Asymptomatic, Prodromal, And Dementia. This Platform Enhances Diagnostic Sensitivity And Specificity By Recognizing Complex Biomarker Patterns, Allowing For Early Detection As Soon As The Amyloid Pathway Is Engaged. Agent Envisions Routine Health Screenings Incorporating Their Blood Test, Similar To Cancer Screenings, To Transform Early Diagnosis And Therapeutic Strategies. They Collaborate With Healthcare Providers And Clinical Laboratories, Including A Partnership With Inovie Group, To Facilitate The Clinical Deployment Of Their Diagnostic Test.